English
Regional settings| Spread | 0.10 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 10.56 |
| Open | 10.41 |
| 1-Year Change | -58.66% |
| Day's Range | 10.13 - 10.58 |
Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The Company holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.
BRIEF: For the fiscal year ended 31 December 2021, Harrow Health Inc revenues increased 48% to $72.5M. Net loss applicable to common stockholders increased from $3.4M to $18.5M. Revenues reflect Product sales, net increase of 43% to $69.1M, Other revenues increase from $392K to $3.4M. Higher net loss reflects Investment losses from Eton Pharmaceutic decrease from $3.3M (income) to $10.1M (expense), Selling.
Common stock, $.001 Par, 02/12, 50M auth., 1,991,508 issd. Insiders own approx. 27.50%. 02/12, 1-for-8 Reverse split. 1-for-5 reverse stock split.
